Navigation Links
New, virulent strain of MRSA poses renewed antibiotic resistance concerns

PORTLAND, Ore. The often feared and sometimes deadly infections caused by MRSA methicillin-resistant Staphylococcus aureus are now moving out of hospitals and emerging as an even more virulent strain in community settings and on athletic teams, and raising new concerns about antibiotic resistance.

Right now, the new community-associated strain of MRSA is responsive to more, but sometimes different antibiotics than its hospital relative, experts say. But those antibiotics will almost certainly lose their effectiveness as they are used more widely, and efforts are under way to combat that issue.

A new study by pharmacy researchers at Oregon State University has identified two antibiotics that appear less likely to cause future antibiotic resistance, and others that if used would allow resistance to emerge more quickly. This analysis, just published in the International Journal of Antimicrobial Agents, offers physicians some direction to help deal with this problem until more research can be done, they said.

"The problem with invasive MRSA infections is very real and is now moving from the hospital setting to the community," said George Allen, an assistant professor in the OSU College of Pharmacy. "The community-based strain in some ways is even more apt to cause serious problems than those most often acquired in hospitals, and increasing quite dramatically in prevalence.

"The good news is that so far the community strain is more treatable, if we can keep it that way," he said.

Staphylococcus aureus, a common bacterium that's often associated with skin infections, was once treated easily by penicillin. But over many years it acquired resistance to that, as well as the penicillin-derivative methicillin and other antibiotics, leaving limited options to address it. Although infections are usually minor, some can spread rapidly, cause pneumonia, tissue necrosis, blood infections, shock and death.

In the new research based on laboratory analysis, scientists identified linezolid and moxifloxacin as two antibiotics that would be effective against, and less apt to induce antibiotic resistance in the new strain of community-associated MRSA. That's of some interest because moxifloxacin, like other antibiotics in its class, has not been traditionally thought of as an appropriate agent for MRSA because resistance to it often develops rapidly.

Antibiotics that are most apt to cause rapid development of resistance against the community-associated strain of MRSA include clindamycin and doxycycline, the research found. The study was supported by the Society of Infectious Diseases Pharmacists.

"We didn't find one perfect choice of a drug that everyone could use and it won't ever develop resistance," Allen said. "That's not surprising, since with constant use every antibiotic breeds resistance to it in various bacteria. Part of the goal here is just to slow down the increase in resistance while we continue to develop new approaches."

More research, animal and clinical trials would still be of value to further explore this issue, Allen said. The issue of antibiotic resistance in general and MRSA resistance in particular is huge and getting worse.

Meanwhile, the general public should be aware that MRSA infections are no longer confined to the hospital, and can be acquired in ordinary community settings, he said. They are often associated with close personal contact, and have been a particular problem with some athletic sports such as wrestling or football when multiple members of a team have been infected.

MRSA usually, but not always shows first as a skin infection, with such symptoms as swelling, pain, pus or fever. Any significant symptoms or evidence of spread of the infection should be seen by a physician, Allen said. Basic first aid soap, water and a bandage on cuts and scrapes is a good first line of defense, he said, and some antibacterial ointments are available that have been proven to have enhanced effectiveness against MRSA infections.

Complicating the issue, experts say, is that the new community-associated strain of MRSA is now showing up in hospitals, as well, and optimal treatment regimens for the two strains may differ.

"Our data suggest that resistance to all of the tested antimicrobials will develop with their continued use," the researchers wrote in their report.


Contact: George Allen
Oregon State University

Related biology news :

1. African thicket rat malaria linked to virulent human form
2. Scripps research scientists identify blood component that turns bacteria virulent
3. CSHL scientists identify new drug target against virulent type of breast cancer
4. Genomes of 2 popular research strains of E. coli sequenced
5. Novel bacterial strains clear algal toxins from drinking water
6. Knee injuries may start with strain on the brain, not the muscles
7. Strained quantum dots show new optical properties
8. Researchers recreate SARS virus, open door for potential defenses against future strains
9. Selective restraints and reduced medication could reduce nursing home falls says 4-year study
10. Scripps scientists develop new tests that identify lethal prion strains quickly and accurately
11. Type 2 diabetes gene predisposes children to obesity
Post Your Comments:
(Date:11/12/2015)... , Nov. 11, 2015   Growing need ... analytical tools has been paving the way for ... determination of discrete analytes in clinical, agricultural, environmental, ... being predominantly used in medical applications, however, their ... sectors due to continuous emphasis on improving product ...
(Date:11/9/2015)... 09, 2015 ... the "Global Law Enforcement Biometrics Market ... --> ) has announced the ... Biometrics Market 2015-2019" report to their ... ( ) has announced the addition ...
(Date:10/29/2015)... MINNETONKA, Minn. , Oct. 29, 2015   ... that supports the entire spectrum of clinical research, is ... the Minnesota High Tech Association (MHTA) as one of ... in the "Software – Small and Growing" category. The ... and individuals who have shown superior technology innovation and ...
Breaking Biology News(10 mins):
(Date:11/30/2015)... November 30, 2015 TapImmune, Inc. ... development of innovative peptide and gene-based immunotherapeutics and vaccines ... announced it will be presenting at the 8 th ... 2015 at 2.30 PM PT. Dr. John N. ... will be giving the presentation and will join TapImmune ...
(Date:11/30/2015)... BETHESDA, Md. , Nov. 30, 2015  Northwest ... biotechnology company developing DCVax® personalized immune therapies for solid ... to adding an additional independent director, and the Company ... investigation of allegations in a recent anonymous internet report ... on both initiatives. Linda Powers stated, ...
(Date:11/27/2015)... PA (PRWEB) , ... November 27, 2015 , ... ... Technical Program that includes over 2,000 technical presentations offered in symposia, oral ... chemistry and applied spectroscopy, covers a wide range of applications such as, but ...
(Date:11/25/2015)... , Nov. 25, 2015  PharmAthene, Inc. (NYSE ... has adopted a stockholder rights plan (Rights Plan) in ... operating loss carryforwards (NOLs) under Section 382 of the ... --> PharmAthene,s use of its NOLs could ... change" as defined in Section 382 of the Code. ...
Breaking Biology Technology: